Gabapentin Capsule
Product Images NDC 87441-034

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 87441-034). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 100 mg (8744103401 Gabapentin 100 mg)

Label for Gabapentin Capsules, USP 100 mg, a prescription oral capsule. The label includes dosage strength, pharmacist dispensing instructions, storage temperature guidelines, and repackaging information by Unit Dose Solutions, Inc. It also notes distribution by Tuckahoe Enterprises, LLC, and contains space for lot, expiration, and quantity details.*

FDA Label Image

Formula (Gabapentin Capsules Usp 1)

A formula depicting the creatinine clearance (CLCr) calculation, showing variables for age, weight, serum creatinine, and an adjustment factor for female patients. This mathematical expression is commonly used to estimate kidney function.*

FDA Label Image

Chem Structure (Gabapentin Capsules Usp 2)

Chemical structure of Gabapentin showing its cyclohexane ring connected to amino and carboxyl functional groups.*

FDA Label Image

10 (Gabapentin Capsules Usp 3)

A line graph comparing mean pain scores over an 8-week period for placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, including a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores, with Gabapentin demonstrating a greater reduction in pain compared to placebo.*

FDA Label Image

10 (Gabapentin Capsules Usp 4)

A line graph depicting mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows the mean pain score from 0 to 10, with placebo showing higher scores than both Gabapentin dosage groups throughout the study.*

FDA Label Image

10 (Gabapentin Capsules Usp 5)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) doses across two studies. Study 1 shows 12% for placebo and 29% for GBP 3600. Study 2 shows 14% for placebo, 32% for GBP 1800, and 34% for GBP 2400. Statistical significance is indicated with p values less than 0.01 and 0.001.*

FDA Label Image

Figure 4 (Gabapentin Capsules Usp 6)

A scatter plot depicting the percentage difference versus daily dose in mg for Gabapentin across three studies labeled as Study a, Study b, and Study c. The x-axis represents the daily dose ranging from 600 mg to 1800 mg, and the y-axis represents the difference percentage ranging from 2% to 22%. Each study is represented by different symbols with corresponding labels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.